DISCORVER GOLIVER THERAPEUTICS
THE CELL THERAPY AND THE REGENERATIVE MEDICINE OF TOMORROW
GOLIVER THERAPEUTICS is a spin-off from the INSERM and University of Nantes (CRTI UMR1064-ITUN-Nantes Hospital), focused on developing cell-based Advanced Therapy Medicinal Products (ATMP) to respond to an urgent unmet medical need in transplantation.
GOLIVER THERAPEUTICS aims to become a Worldwide leader inregenerative medicine in providing the first cell-based therapy product for life-threatening liver failures.
Date of creation : April 2017.
The Solution That Goliver Therapeutics Provides
GoliverTX solution is based on the remarkable and unique ability of the liver to regenerate after injuries (the myth of Prometheus)
➜ ->It is manufactured from pluripotent stem cells, which have unlimited self-renewal ability and can be differentiated
into hepatocytes, the metabolic cells of the liver.
After injection into the patient, the hepatocytes will support liver metabolism and regeneration with the therapeutic benefit of:
➜Patient recovery without liver graft
➜ ""Therapeutic bridge” to liver transplant.
The cell therapy is transient :
➜ After patient healing (or liver transplant), there is no further need of the injected therapeutic cells
➜ Immunosuppression to avoid cell rejection is short-term.
Business Development Advisory Board
Didier HOCH: Chairman : Chairman of the Supervisory Board Pherecydes Former Chairman of the Sanofi Pasteur MSD
Maryvonne HIANCE: VP Business Development : Co-Founder Vice Chairman of the Board and Director for Public Affairs of OSE immunotherapeutics, President of the « HealthTech Investor Days » committee and Vice Chairman of France Biotech
Prof. Thierry GUSTOT : Directeur Médical de la Transplantation Hépatique - Hôpital Erasme, Bruxelles, Belgique; Editor of J. Hep. Reports
Tuan Huy NGUYEN (PhD): CEO and CSO : Co-Founder, Former researcher at INSERM, Expert in the field of liver cell & gene therapy and regenerative medicine
Michel COIGNARD VP Finance: Co-Founder, Former CFO Alcatel, General Foods, Trailer
Scientific Advisory Board
Anne WEBER-BENAROUS (PhD) Former Director INSERM unit Pioneer in stem cell-based liver therapy, Coordinator of Liv-ES and Innovaliv European FP7 projects (2008-2014)
Prof. Didier SAMUEL: Dean of the Paris Sud Faculty of Medicine, Director of the Inserm Unit 1193, Paul-Brousse Hospital, Centre Hépato-Biliaire, Villejuif, France
Prof Alberto Sanchez-Fueyo MD-PhD, Academic Head of Liver Sciences : King’s College London, Expert in Liver Immunotherapy and Transplantation, ORCID 0000-0002-8316-3504
Prof. Faouzi SALIBA Prof. Hepatology : Hepatologist and Transplant critical care intensivist, Coordinator of FULMAR trial
Prof. Thierry GUSTOT: Head Liver Transplant: Erasme Hospital, Bruxelles, Belgium, Editor of J. Hep reports
OTHER ADVISORS AND COLLABORATORS
L. Nguyen: Business development : , CEO Bionure, Former CEO of Sensorion
L. Selig: Business development : CEO CYTOO, co-founder of Hybrigenics
D. Franco: clinical development co-founder, VP of the French National Academy of Surgery, former Head visceral surgery unit, former ANSM expert
JC. Duclos-Vallée: clinician collaborator : CHB Paul Brousse Hospital (Villejuif), coordinator of RHU iLite
A.Dubart-Kupperschmitt: scientific collaborator : U1193 INSERM, Leader of Stem cell and Liver Team
L. Vallier: scientific collaborator: Cambridge University, expert in pluripotent stem cell
The liver is the most complex and metabolically organ (>500 functions) in the body: synthesis, secretion, regulation and detoxification. Severe fulminant live diseases are life-threatening and current solutions are unsatisfactory.
To know more:
Link to ‘CHB Paul-Brousse Hospital” (https://www.centre-hepato-biliaire.org/en/maladies-foie.html)
Link to ‘” American Liver Foundation” (https://liverfoundation.org/for-patients/about-the-liver/diseases-of-the-liver/)
link to TRANSHEPATE (https://www.transhepate.org/)
Link to ELTR (http://www.eltr.org/)
Link to ELPA (https://www.eu-patient.eu/Members/The-EPF-Members/Full-Membership/European-Liver-Patients-organisation–ELPA/)
Link to ERN RARE-LIVER (https://rare-liver.eu/)
LIVER TRANSPLANT WAITING LIST IN EUROPE AND THE UNITED STATES
Sources: EUROTRANSPLANT, AGENCE DE LA BIOMEDECINE, FRANCE ADOT, ELTR (Europe), OPTN (USA)
Liver transplantation is the only proven cure at end-stage disease when the failing liver can no longer provide a minimum level of vital functions. Nevertheless, the urgent unmet medical need remains. Because of timely unavailability graft, of lifelong immunosuppression-associated complications, and
BECAUSE OF THE SHORTAGE OF ORGANS, AN ALTERNATIVE SOLUTION TO LIVER TRANSPLANT IS TO BE FIND. HOW?
➞ By Developing new generations of Advanced Therapy Medicinal Products (ATMP)
➞ By developing a novel cell therapy using the technology of pluripotent stem cells for regenerative medicine – Health of the Future
➞ By developing industrialization for the pharmaceutical cell drug manufacturing, from the raw biological material to bedside – Industry of the Future -.
GOLIVER THERAPEUTICS IS DEVELOPING THIS HEALTH OF THE FUTURE AND THIS INDUSTRY OF THE FUTURE TO BECOME A MAJOR WORLD LEADER IN LIVER REGENERATIVE MEDICINE
“GOLIVER THERAPEUTICS is pioneering liver regeneration with differentiated human pluripotent stem cells.”
The human body contains more than 100,000 billion cells that die and are replaced any time.
➞ In 1950, the concept of adult stem cells explains the renewal of blood and skin.
➞ In 1957, bone marrow transplant in patients begin (E. Donald Thomas), this is the beginning of cell therapy with stem cells.
➞ The early 2000s saw the acceleration of research on human pluripotent stem cells, a biomedical breakthrough rewarded by the Nobel Prize in Medicine in 2012 (J. Gurdon and S. Yamanaka).
➞ Pluripotent stem cells, of embryonic or induced origin (iPS) resulting from the reprogramming of adult cells to a state similar to embryonic cells, have a huge biomedical and pharmaceutical. potential because they proliferate indefinitely in vitro on culture dish while retaining the ability to differentiate into any cells of the body.
➞ They open the perspective of repairing organs and tissues to cure diseases and injuries.
The first clinical trials have already begun and confirm the biomedical interest of differentiated pluripotent stem cells in treating spinal cord injuries (2010), retinal degenerative diseases (2011), heart failure (2014, Prof. Menasché, G. Pompidou Hospital, France), treating diabetes (2018) and graft-versus-host disease (2018).
To know more : ≟
(Ilic et al, Human embryonic and induced pluripotent stem cells in clinical trials, British Medical Bulletin 2015)
Cell Therapy Product
Cell therapy is a promising therapeutic option for liver diseases, as an
alternative to liver transplant.
Injection of hepatocytes isolated from donor livers: > 100 patients (since 1994). Target diseases: genetics, acute liver failure, cirrhosis. Results: clinical improvements, healing without graft, therapeutic bridge. But the problem of organ shortage remains, the amount of isolated cells is limited and these cells do not multiply sufficiently in vitro.
The drug candidate of GOLIVER THERAPEUTICS is an injectable solution containing hepatocytes produced from human pluripotent stem cells, an unlimited source of body cells grown in the laboratory.
PARTNERS, COLLABORATORS AND FINANCIAL SUPPORTS OF THE GOLIVER THERAPEUTICS PROJECT
Co-financing from the European Union (ERDF) of 400 000 € to develop an industrial production process at the scale of one
billion cells to repair the liver without graft. (2018/2020)
8 quai Moncousu – BP 70721
44007 Nantes Cedex, France